Assessment of dementia risk using three common screening tools at baseline predicts incident dementia over the course of about seven years.
Migraines are a significant risk factor for Alzheimer disease (AD) and all-cause dementia.
β-amyloid (Aβ) and cerebrovascular disease burden have divergent effects on longitudinal default mode network and executive control network functional connectivity changes in amnestic MCI and subcortical vascular MCI.
The majority of older adults diagnosed with dementia do not receive specialty care.
Investigators addressed the association between long-term use of hydroxychloroquine therapy and the risk for Alzheimer disease.
Results of a safety review have led to the discontinuation of phase 3 clinical studies of elenbecestat, an investigational oral BACE (beta amyloid cleaving enzyme) inhibitor, which was being assessed for early Alzheimer disease (AD) treatment.
Diffusion tensor image segmentation technique, which characterizes microstructural damage across the cerebellum, identifies damage in cerebral small vessel disease and can predict dementia.
Delirium is highly prevalent in critical care, especially among elderly patients and individuals with dementia. Although rates vary widely across studies, findings suggest delirium affects more than 15% of hospitalized patients. For additional discussion regarding this topic, Neurology Advisor interviewed Leopoldo Pozuelo, MD, MBA, FACP, FACLP, clinical vice chair of psychiatry and psychology at the Cleveland Clinic in Ohio.
The USPSTF concludes that the evidence is currently inadequate for weighing the benefits and harms of screening for cognitive impairment among older adults.
A phase 3 trial evaluating pimavanserin (Acadia) for the treatment of dementia-related psychosis has been stopped early due to positive findings in a planned interim efficacy analysis.